JP2020531465A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020531465A5 JP2020531465A5 JP2020509054A JP2020509054A JP2020531465A5 JP 2020531465 A5 JP2020531465 A5 JP 2020531465A5 JP 2020509054 A JP2020509054 A JP 2020509054A JP 2020509054 A JP2020509054 A JP 2020509054A JP 2020531465 A5 JP2020531465 A5 JP 2020531465A5
- Authority
- JP
- Japan
- Prior art keywords
- hsv
- composition according
- glycoprotein
- composition
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 33
- 241000700584 Simplexvirus Species 0.000 claims 32
- 108020004999 messenger RNA Proteins 0.000 claims 23
- 108090000288 Glycoproteins Proteins 0.000 claims 12
- 102000003886 Glycoproteins Human genes 0.000 claims 12
- 208000009889 Herpes Simplex Diseases 0.000 claims 7
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 claims 6
- 239000012634 fragment Substances 0.000 claims 6
- 230000028993 immune response Effects 0.000 claims 6
- 241000701074 Human alphaherpesvirus 2 Species 0.000 claims 5
- 230000002163 immunogen Effects 0.000 claims 5
- 230000002452 interceptive effect Effects 0.000 claims 5
- 239000002105 nanoparticle Substances 0.000 claims 5
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 3
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 3
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 claims 3
- 150000007523 nucleic acids Chemical group 0.000 claims 3
- 239000002773 nucleotide Substances 0.000 claims 3
- 125000003729 nucleotide group Chemical group 0.000 claims 3
- PTJWIQPHWPFNBW-GBNDHIKLSA-N pseudouridine Chemical group O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-GBNDHIKLSA-N 0.000 claims 3
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 claims 3
- 229940045145 uridine Drugs 0.000 claims 3
- 102100022717 Atypical chemokine receptor 1 Human genes 0.000 claims 2
- 101000678879 Homo sapiens Atypical chemokine receptor 1 Proteins 0.000 claims 2
- 101000807236 Human cytomegalovirus (strain AD169) Membrane glycoprotein US3 Proteins 0.000 claims 2
- 101900111632 Human herpesvirus 1 Envelope glycoprotein C Proteins 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 239000002502 liposome Substances 0.000 claims 2
- BTFXIEGOSDSOGN-KWCDMSRLSA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methyl-1,3-diazinane-2,4-dione Chemical compound O=C1NC(=O)C(C)CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 BTFXIEGOSDSOGN-KWCDMSRLSA-N 0.000 claims 1
- 208000037952 HSV-1 infection Diseases 0.000 claims 1
- 208000000903 Herpes simplex encephalitis Diseases 0.000 claims 1
- 208000037018 Herpes simplex virus encephalitis Diseases 0.000 claims 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010061308 Neonatal infection Diseases 0.000 claims 1
- 229930185560 Pseudouridine Natural products 0.000 claims 1
- PTJWIQPHWPFNBW-UHFFFAOYSA-N Pseudouridine C Natural products OC1C(O)C(CO)OC1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-UHFFFAOYSA-N 0.000 claims 1
- 108091023045 Untranslated Region Proteins 0.000 claims 1
- 230000005875 antibody response Effects 0.000 claims 1
- WGDUUQDYDIIBKT-UHFFFAOYSA-N beta-Pseudouridine Natural products OC1OC(CN2C=CC(=O)NC2=O)C(O)C1O WGDUUQDYDIIBKT-UHFFFAOYSA-N 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 239000003623 enhancer Substances 0.000 claims 1
- 230000003325 follicular Effects 0.000 claims 1
- 210000004392 genitalia Anatomy 0.000 claims 1
- 210000001102 germinal center b cell Anatomy 0.000 claims 1
- 210000002443 helper t lymphocyte Anatomy 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 230000007420 reactivation Effects 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 241001529453 unidentified herpesvirus Species 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023138084A JP7674760B2 (ja) | 2017-08-17 | 2023-08-28 | 単純ヘルペスウイルス糖タンパク質をコードする修飾ｍＲＮＡワクチン及びその使用 |
| JP2025069088A JP2025108645A (ja) | 2017-08-17 | 2025-04-18 | 単純ヘルペスウイルス糖タンパク質をコードする修飾ｍＲＮＡワクチン及びその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762546648P | 2017-08-17 | 2017-08-17 | |
| US62/546,648 | 2017-08-17 | ||
| US201862701019P | 2018-07-20 | 2018-07-20 | |
| US62/701,019 | 2018-07-20 | ||
| PCT/IB2018/056210 WO2019035066A1 (en) | 2017-08-17 | 2018-08-17 | MODIFIED MHRNA VACCINES ENCODING HERPES SIMPLEX VIRUS GLYCOPROTEINS AND USES THEREOF |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023138084A Division JP7674760B2 (ja) | 2017-08-17 | 2023-08-28 | 単純ヘルペスウイルス糖タンパク質をコードする修飾ｍＲＮＡワクチン及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020531465A JP2020531465A (ja) | 2020-11-05 |
| JP2020531465A5 true JP2020531465A5 (enExample) | 2021-09-24 |
| JP7386535B2 JP7386535B2 (ja) | 2023-11-27 |
Family
ID=65362983
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020509054A Active JP7386535B2 (ja) | 2017-08-17 | 2018-08-17 | 単純ヘルペスウイルス糖タンパク質をコードする修飾ｍＲＮＡワクチン及びその使用 |
| JP2023138084A Active JP7674760B2 (ja) | 2017-08-17 | 2023-08-28 | 単純ヘルペスウイルス糖タンパク質をコードする修飾ｍＲＮＡワクチン及びその使用 |
| JP2025069088A Pending JP2025108645A (ja) | 2017-08-17 | 2025-04-18 | 単純ヘルペスウイルス糖タンパク質をコードする修飾ｍＲＮＡワクチン及びその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023138084A Active JP7674760B2 (ja) | 2017-08-17 | 2023-08-28 | 単純ヘルペスウイルス糖タンパク質をコードする修飾ｍＲＮＡワクチン及びその使用 |
| JP2025069088A Pending JP2025108645A (ja) | 2017-08-17 | 2025-04-18 | 単純ヘルペスウイルス糖タンパク質をコードする修飾ｍＲＮＡワクチン及びその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US11141478B2 (enExample) |
| EP (2) | EP4242223A3 (enExample) |
| JP (3) | JP7386535B2 (enExample) |
| CN (2) | CN111246854A (enExample) |
| AU (2) | AU2018316811B2 (enExample) |
| CA (1) | CA3073161A1 (enExample) |
| WO (1) | WO2019035066A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200054737A1 (en) * | 2017-04-26 | 2020-02-20 | Modema TX, Inc. | Herpes simplex virus vaccine |
| AU2018316811B2 (en) | 2017-08-17 | 2023-07-13 | The Trustees Of The University Of Pennsylvania | Modified mRNA vaccines encoding herpes simplex virus glycoproteins and uses thereof |
| AU2020233995A1 (en) * | 2019-03-12 | 2021-09-23 | BioNTech SE | Therapeutic RNA for prostate cancer |
| CN111568856B (zh) * | 2020-06-24 | 2021-07-06 | 珠海舒桐医疗科技有限公司 | 一种阴道凝胶制剂及其制备方法 |
| WO2022002783A1 (en) * | 2020-06-29 | 2022-01-06 | Glaxosmithkline Biologicals Sa | Adjuvants |
| US12419948B2 (en) | 2020-08-31 | 2025-09-23 | The Broad Institute, Inc. | Immunogenic compositions and use thereof |
| EP4225360A1 (en) | 2020-10-08 | 2023-08-16 | Virothera Limited | Vaccine compositions |
| EP4032547A1 (en) * | 2021-01-20 | 2022-07-27 | GlaxoSmithKline Biologicals S.A. | Hsv1 fce derived fragements for the treatment of hsv |
| EP4032546A1 (en) * | 2021-01-20 | 2022-07-27 | GlaxoSmithKline Biologicals S.A. | Therapeutic viral vaccine |
| EP4284335A1 (en) | 2021-02-01 | 2023-12-06 | RegenxBio Inc. | Gene therapy for neuronal ceroid lipofuscinoses |
| CA3211277A1 (en) | 2021-03-11 | 2022-09-15 | Marina TAMBASCO STUDART | Vaccine compositions and methods for treating hsv |
| CN118217388A (zh) * | 2022-12-19 | 2024-06-21 | 南京奥罗生物科技有限公司 | 单纯疱疹病毒疫苗及其应用 |
| TW202434263A (zh) * | 2023-01-27 | 2024-09-01 | 德商拜恩技術股份公司 | 用於遞送單純疱疹病毒醣蛋白ｃ、醣蛋白ｄ、及醣蛋白ｅ抗原之醫藥組成物及相關方法 |
| WO2024163918A1 (en) * | 2023-02-02 | 2024-08-08 | University Of Houston System | Mrna vaccine for herpes simplex virus |
| WO2024249967A1 (en) * | 2023-06-02 | 2024-12-05 | The Trustees Of The University Of Pennsylvania | Rna vaccines encoding herpes simplex virus glycoproteins and uses thereof |
| WO2025030165A1 (en) * | 2023-08-03 | 2025-02-06 | BioNTech SE | Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods |
| AU2024318951A1 (en) | 2023-08-03 | 2026-03-12 | BioNTech SE | Rna compositions encoding herpes simplex virus glycoprotein e and/or glycoprotein i antigens and uses thereof |
| AU2024316307A1 (en) * | 2023-08-03 | 2026-02-26 | BioNTech SE | Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods |
| AU2024316992A1 (en) | 2023-08-03 | 2026-03-12 | BioNTech SE | Rna compositions encoding herpes simplex virus glycoprotein b antigens and uses thereof |
| WO2025072383A1 (en) | 2023-09-25 | 2025-04-03 | The Broad Institute, Inc. | Viral open reading frames, uses thereof, and methods of detecting the same |
| WO2025097055A2 (en) | 2023-11-02 | 2025-05-08 | The Broad Institute, Inc. | Compositions and methods of use of t cells in immunotherapy |
| WO2025109008A1 (en) | 2023-11-20 | 2025-05-30 | Redbiotec Ag | Novel vaccine compositions and methods for treating hsv |
| WO2025129158A1 (en) | 2023-12-15 | 2025-06-19 | The Broad Institute, Inc. | Engineered arc delivery vesicles and uses thereof |
| WO2025175124A1 (en) * | 2024-02-15 | 2025-08-21 | Albert Einstein College Of Medicine | Recombinant herpes simplex virus glycoprotein b for treatment and prevention of herpes simplex virus infections |
| WO2025212831A1 (en) * | 2024-04-03 | 2025-10-09 | The Trustees Of The University Of Pennsylvania | Methods of inducing an anti-hsv b-cell immune response |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995026204A1 (en) | 1994-03-25 | 1995-10-05 | Isis Pharmaceuticals, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
| RS63964B1 (sr) | 2005-08-23 | 2023-03-31 | Univ Pennsylvania | Rnk koja sadrži modifikovane nukleozide i postupci za njenu upotrebu |
| EP2521786B1 (en) | 2006-07-20 | 2015-06-24 | Vical Incorporated | Compositions for vaccinating against hsv-2 |
| US20130028925A1 (en) | 2006-12-28 | 2013-01-31 | Harvey Friedman | Herpes simplex virus combined subunit vaccines and methods of use thereof |
| US9284355B2 (en) * | 2006-12-28 | 2016-03-15 | The Trustees Of The University Of Pennsylvania | Herpes simplex virus combined subunit vaccines and methods of use thereof |
| AU2010249330B2 (en) * | 2009-05-22 | 2015-11-05 | Genocea Biosciences Inc. | Vaccines against Herpes Simplex Virus type 2: compositions and methods for eliciting an immune response |
| EP2496700B1 (en) | 2009-11-04 | 2017-03-01 | The University Of British Columbia | Nucleic acid-containing lipid particles and related methods |
| US9192661B2 (en) * | 2010-07-06 | 2015-11-24 | Novartis Ag | Delivery of self-replicating RNA using biodegradable polymer particles |
| US9770463B2 (en) * | 2010-07-06 | 2017-09-26 | Glaxosmithkline Biologicals Sa | Delivery of RNA to different cell types |
| US20130323269A1 (en) | 2010-07-30 | 2013-12-05 | Muthiah Manoharan | Methods and compositions for delivery of active agents |
| SI2850431T1 (en) * | 2012-05-16 | 2018-08-31 | Immune Design Corp. | Vaccines for hsv-2 |
| WO2015089340A1 (en) * | 2013-12-11 | 2015-06-18 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Human herpesvirus trimeric glycoprotein b, protein complexes comprising trimeric gb and their use as vaccines |
| DK3142750T3 (da) * | 2014-05-13 | 2020-09-14 | Univ Pennsylvania | Sammensætninger omfattende aav, som udtrykker dobbelt-antistofkonstrukter og anvendelser deraf |
| CA2962639A1 (en) * | 2014-10-01 | 2016-04-07 | Jingang Medicine (Australia) Pty Ltd | Therapeutic compositions and methods for inducing an immune response to herpes simplex virus type 2 (hsv-2) |
| EP3289083A4 (en) | 2015-04-27 | 2018-12-19 | The Trustees Of The University Of Pennsylvania | Nucleoside-modified rna for inducing an adaptive immune response |
| US10758694B2 (en) | 2015-07-09 | 2020-09-01 | Hoyt Medical LLC | Systems and methods for treating an airway using a tapered adapter device |
| BR112018008090A2 (pt) | 2015-10-22 | 2018-11-13 | Modernatx Inc | vacina de vírus do herpes simplex. |
| CA3002819A1 (en) * | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Sexually transmitted disease vaccines |
| IL317855A (en) * | 2016-10-26 | 2025-02-01 | Acuitas Therapeutics Inc | mRNA vaccines with lipid nanoparticles |
| US20200054737A1 (en) | 2017-04-26 | 2020-02-20 | Modema TX, Inc. | Herpes simplex virus vaccine |
| AU2018316811B2 (en) | 2017-08-17 | 2023-07-13 | The Trustees Of The University Of Pennsylvania | Modified mRNA vaccines encoding herpes simplex virus glycoproteins and uses thereof |
-
2018
- 2018-08-17 AU AU2018316811A patent/AU2018316811B2/en active Active
- 2018-08-17 WO PCT/IB2018/056210 patent/WO2019035066A1/en not_active Ceased
- 2018-08-17 CA CA3073161A patent/CA3073161A1/en active Pending
- 2018-08-17 JP JP2020509054A patent/JP7386535B2/ja active Active
- 2018-08-17 EP EP23169155.1A patent/EP4242223A3/en active Pending
- 2018-08-17 US US16/640,008 patent/US11141478B2/en active Active
- 2018-08-17 CN CN201880068068.XA patent/CN111246854A/zh active Pending
- 2018-08-17 EP EP18846061.2A patent/EP3668520A4/en active Pending
- 2018-08-17 CN CN202410526392.9A patent/CN118370812A/zh active Pending
-
2021
- 2021-06-17 US US17/349,929 patent/US11793872B2/en active Active
-
2023
- 2023-08-28 JP JP2023138084A patent/JP7674760B2/ja active Active
- 2023-09-19 US US18/470,325 patent/US20240024463A1/en active Pending
- 2023-10-13 AU AU2023248194A patent/AU2023248194A1/en active Pending
-
2025
- 2025-04-18 JP JP2025069088A patent/JP2025108645A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020531465A5 (enExample) | ||
| JP2023153423A5 (enExample) | ||
| Chakravorty et al. | EBV-associated diseases: Current therapeutics and emerging technologies | |
| JP2025108645A5 (enExample) | ||
| Cui et al. | Rabbits immunized with Epstein-Barr virus gH/gL or gB recombinant proteins elicit higher serum virus neutralizing activity than gp350 | |
| IL302102A (en) | shared neoantigens | |
| JP2016136950A5 (enExample) | ||
| Shastri et al. | Monitoring peptide processing for MHC class I molecules in the endoplasmic reticulum | |
| JP2013527758A5 (enExample) | ||
| Sausen et al. | Mechanisms of T cell evasion by Epstein-Barr virus and implications for tumor survival | |
| JP2013545448A5 (enExample) | ||
| JP2023106591A (ja) | 既存の微生物免疫を利用した癌処置 | |
| Stab et al. | Protective efficacy and immunogenicity of a combinatory DNA vaccine against Influenza A Virus and the Respiratory Syncytial Virus | |
| Chen et al. | New insights into Epstein-Barr virus-associated tumors: Exosomes | |
| JP2023017853A (ja) | 新規な癌抗原及び方法 | |
| JP2019516768A5 (enExample) | ||
| Amador-Molina et al. | Vaccination with human papillomavirus-18 E1 protein plus α-galactosyl-ceramide induces CD8+ cytotoxic response and impairs the growth of E1-expressing tumors | |
| JP2010535504A5 (enExample) | ||
| Clemens | Epstein-Barr virus: inhibition of apoptosis as a mechanism of cell transformation | |
| Belin et al. | Uncoupling ribosome biogenesis regulation from RNA polymerase I activity during herpes simplex virus type 1 infection | |
| JP2025138799A (ja) | 免疫記憶に基づく新規疾患治療および予防 | |
| KR20230156744A (ko) | 백신 조성물 및 hsv 치료 방법 | |
| KR20230107553A (ko) | 헤르페스바이러스 폴리에피토프 백신 | |
| Hicks et al. | Alterations in cellular and viral microRNA and cellular gene expression in Marek's disease virus-transformed T-cell lines treated with sodium butyrate | |
| CN119487195A (zh) | 疫苗及其用于治疗wnt相关癌症的方法 |